

Special Issue

NASH as an Inducer of Hepatocellular Carcinoma (HCC)

Message from the Guest Editors

Non-alcoholic fatty liver disease (NAFLD) can progress into non-alcoholic steato-hepatitis (NASH), which is characterised by steatosis and inflammation, and in some cases, this may also develop into fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Factors influencing NASH-HCC progression include: estrogen, fibrosis, insulin, and circadian rhythm disruption. Currently, therapeutic options for NASH-HCC are limited, and survival rates are poor.

This Special Issue supports new insights into basic and clinical research on NASH-HCC. This collection of papers will shed light on the pathophysiology, clinical problems, diagnostic methods, therapeutic approaches and lifestyle adaptations of NASH-HCC, as well as on its systemic risk factors. The overall aim of this Special Issue is to raise awareness of the opportunities and challenges in translational NASH-HCC research, i.e., to explore possible answers that basic research can provide, and vice versa, to translate basic research questions to human situations. This Special Issue invites all junior and senior researchers and clinicians in the field of NASH-HCC, to share their novel findings and new ideas.

Guest Editors

Prof. Dr. Ronit Shiri-Sverdlov

NUTRIM, Department of Molecular Genetics, Maastricht University, Maastricht, The Netherlands

Dr. Sabine Baumgartner

Department of Nutrition and Movement Sciences, Maastricht University, Maastricht, The Netherlands

Deadline for manuscript submissions

closed (31 January 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/80073

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).